Results for gilead sciences

Add to feed Create your own feed

Latest

Gilead Sciences announced its Covid-19 therapy drug, remdesivir, will cost private insurers $520 for a single vial, hundreds of times its production cost, which researchers have estimated at 93 cents per dose.

Health experts slam US deal for large supply of virus drug The US government announced this week that it had an agreement with Gilead Sciences to make the bulk of their production of remdesivir for the next three months available to AmericansRead--

tweet picture

Brussels is in talks with Gilead Sciences to reserve doses of the drug remdesivir to combat coronavirus

SVB Leerink Weighs in on Gilead Sciences, Inc.’s Q1 2021 Earnings $GILD

The American pharmaceutical giant Gilead Sciences is coming under scrutiny for agreements that activists say will restrict global access to remdesivir, an experimental antiviral drug that has shown promise in treating COVID-19.

At least somebody was thinking ahead. This is how Gilead Sciences prepared for the coronavirus pandemic

Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences - ScienceDirect Worth a reread in light of Fauci, Gilead, and Remdesivir pricing.

Gilead Sciences agrees to make the bulk of their production of remdesivir available to Americans for the next three months

South Korea said it will begin talks with Gilead Sciences to purchase supplies of remdesivir, one of the few treatments shown to alter the course of COVID-19

$GILD: Gilead Sciences will present Phase 1 trial results supporting further evaluation of a six-month dosing...

Loading
Loading

Most relevant

NEWS: HHS has announced an agreement to secure large supplies of the drug remdesivir for the United States from Gilead Sciences through September, allowing American hospitals to purchase the drug in amounts allocated by HHS and state health departments.

After weeks of donating the antiviral drug remdesivir to hospitals with severely ill coronavirus patients, the drug’s maker, Gilead Sciences, announced that it has settled on a price: $390 per vial, which works out to be roughly $2,340 per treatment course

Gilead Sciences says their COVID-19 treatment will cost a U.S. patient with insurance $3,120:

tweet picture

A study funded by Gilead Sciences evaluating the use of its drug remdesivir to treat 53 seriously ill COVID-19 patients found that some got better. But there was no control group, so strong conclusions weren't possible.

BREAKING: Gilead Sciences says it's aware of positive data emerging from the study of remdesivir for the treatment of COVID-19, and that the trial has met its primary endpoint

This is a massive scandal Trump's FDA just granted a drug that is being used to treat coronavirus patients, developed previously by Gilead Sciences, "orphan" status, giving the company seven years of exclusivity. by , @fastlerner  @lhfang 

BREAKING: The Food and Drug Administration acted after preliminary results from a government-sponsored study showed that Gilead Sciences’ Remdesivir shortened the time to recover by 31 percent for hospitalized COVID-19 patients.

Japan on Thursday approved Gilead Sciences Inc's remdesivir as a treatment for COVID-19, making it the country's first officially authorized drug to tackle the coronavirus disease.

#BREAKING COVID-19: Gilead Sciences reports positive data from trial of antiviral drug #remdesivir 

tweet picture

After The Intercept’s story, Gilead Sciences announced that it has submitted a request to rescind the exclusive marketing rights to a promising coronavirus treatment.

Loading
Loading